Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986504 + nab-paclitaxel/gemcitabine in MTAP-deleted metastatic pancreatic ductal adenocarcinoma
CTR20254826Phase 3Active
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of MRTX1719 in pancreatic adenocarcinoma (PDAC), sponsored by Bristol Myers Squibb. Started Mar 2026; status: active.
02
Drugs
MRTX1719
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on CTR20254826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254826.